Close
Chris Yook represents clients in actions pursued by antitrust enforcement agencies and in complex litigation, including some of the largest class actions. His recent matters include obtaining one of the first dismissals of a corporate defendant in the In re Generic Pharmaceuticals Pricing Antitrust Litigation. He also regularly advises public and private companies on the antitrust implications of strategic business decisions.
Chris is recommended in the Legal 500 US guide and he has been named a “Rising Star” for antitrust litigation in Washington SuperLawyers from 2016 through 2021. He currently serves in a leadership position in the ABA Section of Antitrust Law as Vice-Chair of the Content Committee. Chris also sits on the executive board of the Asian Pacific American Bar Association of Maryland and is an American Bar Foundation Fellow.
Publications
- Contributor, Antitrust Law Developments (8th ed.)
- Contributor, 2018 Annual Review of Antitrust Law Developments
- Contributor, 2017 Annual Review of Antitrust Law Developments
- Perils of the Perilous-Leading Theory and Output Decisions, Antitrust Magazine, Vol. 33 No. 3 (2019)
- A Call for Greater Consistency in the Failing Firm Defense, 17-3 ABA Antitrust Source 3 (2017)
- Antitrust Post-Mortem of the Health Insurance Merger Decisions, American Health Lawyers Association
- Avoiding Failure: Applying Decision Theory to the Eminent Domain Jurisprudence, 20 Fed. Cir. B.J. 443 (2011)
back
